AzTrials
AzTrials

Malignant TumorsPhase 1/2NCT07112222

A Study of LM-350 in Subjects With Advanced Solid Tumours

A Phase 1/2 study testing LM-350 for injection in people with Malignant Tumors, run by LaNova Medicines Limited at 4 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Malignant Tumors
What is being tested?
LM-350 for injection
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
4 sitesin 2 countries
Study dates
28 Aug 2025to 30 Jun 2030
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
  • Participant must be ≥18 years or the legal age of consent at the time of signing the ICF.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Life expectancy ≥ 3 months.
  • Patients with advanced solid tumors confirmed by histopathological diagnosis who have failed standard treatment, are intolerant to standard treatment, or for whom standard treatment is currently unsuitable.
  • Pre-treatment archived tumour tissue (within 3 years) or on-treatment tumour biopsy could be provided for biomarker analysis.
Show all 9Show fewer
  • Must have at least one measurable lesion according to RECIST v1.1.
  • Adequate organ and bone marrow function as defined by protocol.
  • Subjects who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Who cannot join

  • Participate in any other clinical trial within 28 days prior to 1st dosing of LM-350.
  • Subjects who have received treatment with the same targeting.
  • History of ≥ Grade 3 late diarrhea during or after previous treatment with a topoisomerase inhibitor.
  • Subjects who have received the following anti-tumor treatments within the specified time periods prior to the first dosing of LM-350.
  • Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
  • Subjects with uncontrolled tumour-related pain.
Show all 25Show fewer
  • Subjects with known central nervous system (CNS) or meningeal metastasis.
  • Subjects who have clinically uncontrollable third-space fluid accumulation.
  • Subjects who experienced grade 3 or higher hypersensitivity to the treatment that contains monoclonal antibody.
  • Subjects who take systemic corticosteroids (≥ 10 mg/day of prednisone or equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dose of LM-350.
  • Has a history of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, and any autoimmune, or prior pneumonectomy.
  • Use of any live attenuated vaccines within 28 days prior to 1st dosing of LM-350.
  • Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for > 2 weeks prior to the first dose of LM-350.
  • Subjects with active or a documented history of chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease).
  • Subjects with complete or incomplete intestinal obstruction within 3 months prior to the first dose of the study drug , orpatients who are currently at the risk of intestinal perforation.
  • Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-350.
  • Subjects who have severe cardiovascular disease.
  • Subjects who have uncontrolled or severe illness.
  • Subjects who have a history of immunodeficiency disease.
  • HIV infection, active infection including tuberculosis, HBV and HCV infection.
  • Subjects who have other active malignancies which are likely to require the treatment.
  • Child-bearing potential female who have positive results in pregnancy test or are lactating.
  • Subjects who have psychiatric illness or disorders that may preclude study compliance.
  • Subject who is judged as not eligible to participate in this study by the investigator.

Trial locations and contacts

4 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Alex Yuan contact

+8615901815211

alexyuan@lanovamed.com

4 sites in 2 countries

Australia3 sites, 3 recruiting

  • Cancer Research SA

    Adelaide, South Australia

    Vineet kwatra

    Recruiting

  • Peninsula and South Eastern Haematology and Oncology Group

    Frankston, Victoria

    Dr Vinod Ganju

    Recruiting

  • Cancer Care Wollongong Pty Limited

    Wollongong, New South Wales

    Udit Nindra

    Recruiting

Other trials in Australia

China1 site, 1 recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality

    Lin Shen

    Not yet recruiting

Other trials in China

About this study

Official title: A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients With Advanced Solid Tumors

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350.

For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.

Being tested
LM-350 for injection
Medical subject headings
Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LM-350 for injectionDrug

    Q3W,Intravenous Drip

Study groups in NCT07112222
Study groupRoleWhat they receive
Phase I Dose Escalation Part and Dose Confirmation PartExperimentalNot described
Receives: Drug: LM-350 for injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of dose-limitingtoxicity (DLT)

    Phase I

    Measured: 78 weeks

  2. Incidence of Treatment-Emergent Adverse Events (AEs)

    Phase I

    Measured: 78 weeks

  3. Incidence of serious adverse events (SAEs)

    Phase I

    Measured: 78 weeks

  4. Temperature (Celsius)

    Phase I

    Measured: 78 weeks

  5. Pulse in BPM(Beat per Minute)

    Phase I

    Measured: 78 weeks

  6. Blood Pressure in mmHg

    Phase I

    Measured: 78 weeks

  7. Weight in Kg

    Phase I

    Measured: 78 weeks

  8. Height in centimeter

    Phase I

    Measured: 78 weeks

  9. Blood Routine examination -> Complete Blood Count

    Phase I

    Measured: 78 weeks

  10. Urine Routine examination ->Urinalysis

    Phase I

    Measured: 78 weeks

  11. Blood Biochemistry test -> Electrolytes and Metabolic Parameters

    Phase I

    Measured: 78 weeks

  12. Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT), International normalized

    Phase I

    Measured: 78 weeks

  13. Pregnancy test

    Phase I

    Measured: 78 weeks

  14. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Phase I

    Measured: 78 weeks

  15. 12-lead electrocardiogram (ECG) in HR

    Phase I

    Measured: 78 weeks

  16. 12-lead electrocardiogram (ECG) in RR

    Phase I

    Measured: 78 weeks

  17. 12-lead electrocardiogram (ECG) in QRS

    Phase I

    Measured: 78 weeks

  18. 12-lead electrocardiogram (ECG) in QT

    Phase I

    Measured: 78 weeks

  19. 12-lead electrocardiogram (ECG) in QTcF

    Phase I

    Measured: 78 weeks

  20. ECOG(Eastern Cooperative Oncology Group) score

    Phase I

    Measured: 78 weeks

  21. Objective Response Rate (ORR)

    Phase II

    Measured: 130 weeks

Secondary outcomes (38)

  1. Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)

    Phase I/II

    Measured: 130 weeks

  2. PK Parameter:Time of Maximum Observed Concentration (Tmax)

    Phase I/II

    Measured: 130 weeks

  3. PK Parameter: Area Under the Concentration-time Curve(AUC)

    Phase I/II

    Measured: 130 weeks

  4. PK Parameter: Steady State Maximum Concentration(Cmax,ss) PK Parameter: Steady State Maximum Concentration(Cmax,ss)

    Phase I/II

    Measured: 130 weeks

  5. PK Parameter: Steady State Minimum Concentration(Cmin,ss)

    Phase I/II

    Measured: 130 weeks

  6. PK Parameter: Systemic Clearance at Steady State (CLss)

    Phase I/II

    Measured: 130 weeks

  7. PK Parameter: Accumulation Ratio (Rac)

    Phase I/II

    Measured: 130 weeks

  8. PK Parameter: Elimination Half-life (t1/2)

    Phase I/II

    Measured: 130 weeks

  9. PK Parameter: Volume of Distribution at Steady-State (Vss)

    Phase I/II

    Measured: 130 weeks

  10. PK Parameter: Degree of Fluctuation (DF)

    Phase I/II

    Measured: 130 weeks

  11. Immunogenicity testing->Anti-Drug Antibody test

    Phase I/II

    Measured: 130 weeks

  12. Objective Response Rate (ORR)

    Phase I

    Measured: 130 weeks

  13. Duration of Response (DOR) in Month

    Phase I/II

    Measured: 130 weeks

  14. Disease control rate (DCR) in percentage

    Phase I/II

    Measured: 130 weeks

  15. Progression-free survival (PFS) in Month

    Phase I/II

    Measured: 130 weeks

  16. Overall survival (OS) in Month

    Phase I/II

    Measured: 130 weeks

  17. Changes of target lesions from baseline in Millimeter

    Phase I/II

    Measured: 130 weeks

  18. Incidence of adverse events (AEs)

    Phase II

    Measured: 130 weeks

  19. Incidence of serious adverse events (SAEs)

    Phase II

    Measured: 130 weeks

  20. Temperature (Celsius)

    Phase II

    Measured: 130 weeks

  21. Pulse in BPM(Beat per Minute)

    Phase II

    Measured: 130 weeks

  22. Blood Pressure in mmHg

    Phase II

    Measured: 130 weeks

  23. Weight in Kg

    Phase II

    Measured: 130 weeks

  24. Height in centimeter

    Phase II

    Measured: 130 weeks

  25. Blood Routine examination -> Complete Blood Count

    Phase II

    Measured: 130 weeks

  26. Urine Routine examination ->Urinalysis

    Phase II

    Measured: 130 weeks

  27. Blood Biochemistry test -> Electrolytes and Metabolic Parameters

    Phase II

    Measured: 130 weeks

  28. Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT), International normalized ratio (INR)

    Phase II

    Measured: 130 weeks

  29. Pregnancy test

    Phase II

    Measured: 130 weeks

  30. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage

    Phase II

    Measured: 130 weeks

  31. ECOG(Eastern Cooperative Oncology Group) score

    Phase II

    Measured: 130 weeks

  32. 12-lead electrocardiogram (ECG) in HR

    Phase II

    Measured: 130 weeks

  33. 12-lead electrocardiogram (ECG) in RR

    Phase II

    Measured: 130 weeks

  34. 12-lead electrocardiogram (ECG) in PR

    Phase II

    Measured: 130 weeks

  35. 12-lead electrocardiogram (ECG) in QRS

    Phase II

    Measured: 130 weeks

  36. 12-lead electrocardiogram (ECG) in QT

    Phase II

    Measured: 130 weeks

  37. 12-lead electrocardiogram (ECG) in QTcF

    Phase II

    Measured: 130 weeks

  38. Biomarker test -> Tumor tissue biomarker test

    Phase I/II

    Measured: 130 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2025
  2. Study start28 Aug 2025
  3. Primary completion30 Jun 2028 (estimated)
  4. Study completion30 Jun 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential
Masking
None (open label)
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07112222
Sponsor's protocol ID
LM350-01-101
Status last verified
Jan 2026
First submitted
16 Jul 2025
Last updated
26 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing LM-350 for injection in people with Malignant Tumors, run by LaNova Medicines Limited at 4 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Australia, China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Alex Yuan (+8615901815211, alexyuan@lanovamed.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of dose-limitingtoxicity (DLT) (time frame: 78 weeks). The study lists 21 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07112222.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in